Bisphosphonate uncertainties linger at FDA

Eight months after an FDA panel recommended clarifying the duration of use in labels of bisphosphonates for osteoporosis, the agency said

Read the full 217 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE